A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab plus /- chemotherapy in patients with HER2-positive metastatic breast cancer
- Resource Type
- Journal
- Source
CANCER RESEARCH ; FEB 2017, 77 2p. Supplement: 4- Subject
- Language
- English
- ISSN
- 15387445